This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Trial of octreotide in recurrent variceal bleeding

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

32 patients with biopsy-proven hepatic cirrhosis and a first variceal bleed were randomised to sclerotherapy alone or sclerotherapy plus six months of octreotide therapy.

The patients and clinicians were not blinded.

The main outcomes reported were:

  • frequency of rebleeding:
    • during the 6 months of the trial the number of patients who rebled was:
      • 1/16 in the combined octreotide/sclerotherapy group
      • 7/16 in the sclerotherapy alone group
      • p=0.037

  • mortality:
    • during the 6 months the mortality rate was:
      • 0/16 in the combined octreotide/sclerotherapy group
      • 5/16 in the sclerotherapy alone group
      • p<0.02



  • change in portal pressure:
    • during the 6 months the change in portal pressure was:
      • -6.0 mmHg in the combine treatment group
      • +1.5 mmHg in the sclerotherapy alone group

Reference:

  • Jenkins, SA. et al. (1997). Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ, 315, 1138-41.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.